1. Home
  2. IMMR vs AGEN Comparison

IMMR vs AGEN Comparison

Compare IMMR & AGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Immersion Corporation

IMMR

Immersion Corporation

HOLD

Current Price

$6.80

Market Cap

229.4M

Sector

Technology

ML Signal

HOLD

Logo Agenus Inc.

AGEN

Agenus Inc.

HOLD

Current Price

$3.14

Market Cap

126.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
IMMR
AGEN
Founded
1993
1994
Country
United States
United States
Employees
N/A
N/A
Industry
Computer peripheral equipment
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
229.4M
126.2M
IPO Year
1999
2000

Fundamental Metrics

Financial Performance
Metric
IMMR
AGEN
Price
$6.80
$3.14
Analyst Decision
Strong Buy
Buy
Analyst Count
2
2
Target Price
$12.25
$14.50
AVG Volume (30 Days)
562.7K
636.2K
Earning Date
12-19-2025
11-10-2025
Dividend Yield
4.41%
N/A
EPS Growth
57.07
N/A
EPS
2.04
N/A
Revenue
$163,133,000.00
$106,829,000.00
Revenue This Year
$988.71
$67.15
Revenue Next Year
$109.72
N/A
P/E Ratio
$3.33
N/A
Revenue Growth
338.21
N/A
52 Week Low
$5.65
$1.38
52 Week High
$9.07
$7.34

Technical Indicators

Market Signals
Indicator
IMMR
AGEN
Relative Strength Index (RSI) 52.53 26.40
Support Level $6.36 $3.01
Resistance Level $6.95 $4.00
Average True Range (ATR) 0.20 0.25
MACD 0.01 -0.05
Stochastic Oscillator 60.27 11.26

Price Performance

Historical Comparison
IMMR
AGEN

About IMMR Immersion Corporation

Immersion Corp is focused on the creation, design, development, and licensing of haptic technologies that allow people to use its sense of touch more fully as it involves engaging with products and experience the digital world. The company's software focuses on applications in mobile devices, wearables, consumer, and gaming devices markets. It generates revenue from royalty and license fees, and development contract and service fees. Geographically, the company generates a majority of its revenue from Japan, followed by Korea, Germany, United States of America and other countries.

About AGEN Agenus Inc.

Agenus Inc is an American clinical-stage company with a pipeline of therapies designed to activate the body's immune system to fight cancer and infections, including immune-modulatory antibodies, adoptive cell therapies through its subsidiary MiNK Therapeutics Inc. and vaccine adjuvants through its subsidiary SaponiQx Inc. This robust product pipeline is supported by company's in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. The company's antibody candidates are botensilimab (a proprietary next-generation Fc-engineered CTLA-4 antibody, also known as AGEN1811) and balstilimab (a PD-1 antibody).

Share on Social Networks: